JP2005525365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525365A5 JP2005525365A5 JP2003572988A JP2003572988A JP2005525365A5 JP 2005525365 A5 JP2005525365 A5 JP 2005525365A5 JP 2003572988 A JP2003572988 A JP 2003572988A JP 2003572988 A JP2003572988 A JP 2003572988A JP 2005525365 A5 JP2005525365 A5 JP 2005525365A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- alkynyl
- alkyl
- alkenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001475 halogen functional group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 claims 2
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 2
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 108010025083 TRPV1 receptor Proteins 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- -1 acyclic hydrocarbon Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36017202P | 2002-03-01 | 2002-03-01 | |
| US41108402P | 2002-09-17 | 2002-09-17 | |
| PCT/US2003/006107 WO2003074520A1 (en) | 2002-03-01 | 2003-02-28 | Thiadiazolylpiperazine derivatives useful for treating or preventing pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525365A JP2005525365A (ja) | 2005-08-25 |
| JP2005525365A5 true JP2005525365A5 (https=) | 2006-04-06 |
| JP4663984B2 JP4663984B2 (ja) | 2011-04-06 |
Family
ID=27791632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003572988A Expired - Fee Related JP4663984B2 (ja) | 2002-03-01 | 2003-02-28 | 疼痛の治療または防止に有用なチアジアゾリルピペラジン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6974818B2 (https=) |
| EP (1) | EP1487829B1 (https=) |
| JP (1) | JP4663984B2 (https=) |
| AT (1) | ATE375341T1 (https=) |
| AU (1) | AU2003225617A1 (https=) |
| CY (1) | CY1107850T1 (https=) |
| DE (1) | DE60316779T2 (https=) |
| DK (1) | DK1487829T3 (https=) |
| ES (1) | ES2295609T3 (https=) |
| PT (1) | PT1487829E (https=) |
| WO (1) | WO2003074520A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100891887B1 (ko) | 2001-01-29 | 2009-04-03 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1ｈ)-피리돈을 활성 성분으로서 함유하는의약 제제 |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
| WO2007062048A2 (en) * | 2005-11-21 | 2007-05-31 | Scripps Research Inst | Role of proteoglycans in drug dependence |
| JP4695395B2 (ja) * | 2002-12-13 | 2011-06-08 | ニューロジェン・コーポレーション | 疼痛治療用の併用療法 |
| ES2288641T3 (es) * | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta. |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| US7524515B2 (en) * | 2003-01-10 | 2009-04-28 | Mutual Pharmaceuticals, Inc. | Pharmaceutical safety dosage forms |
| DE602004003172T2 (de) * | 2003-03-21 | 2007-09-27 | Dynogen Pharmaceuticals Inc., Waltham | Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| US20050009841A1 (en) * | 2003-07-11 | 2005-01-13 | Zheng Guo Zhu | Novel amides useful for treating pain |
| US7129235B2 (en) | 2003-07-11 | 2006-10-31 | Abbott Laboratories | Amides useful for treating pain |
| SI1867644T1 (sl) * | 2003-07-24 | 2009-10-31 | Euro Celtique Sa | Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine |
| EP1867644B1 (en) * | 2003-07-24 | 2009-05-20 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| PL1942106T3 (pl) * | 2003-08-01 | 2012-02-29 | Euro Celtique Sa | Środki lecznicze użyteczne do leczenia bólu |
| EP1664041B1 (en) * | 2003-09-22 | 2008-07-02 | Euro-Celtique S.A. | Phenyl-carboxamide compounds useful for treating pain |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| CA2559285A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
| CA2559282A1 (en) * | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| JPWO2006028161A1 (ja) * | 2004-09-09 | 2008-05-08 | 財団法人乙卯研究所 | セロトニン５−ｈｔ３受容体作動薬 |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| AU2013211455B2 (en) * | 2005-09-19 | 2017-12-07 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration |
| CN102743382B (zh) * | 2005-09-19 | 2016-12-07 | 诺伊罗纳森特公司 | 刺激神经形成和抑制神经元变性的方法和组合物 |
| DE102005062986A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| DK2142529T3 (da) * | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| JP2011503075A (ja) * | 2007-11-09 | 2011-01-27 | ノバルティス アーゲー | エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド |
| WO2009151683A2 (en) * | 2008-03-12 | 2009-12-17 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| JP2012508768A (ja) * | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
| WO2012158844A1 (en) | 2011-05-17 | 2012-11-22 | Shionogi & Co., Ltd. | Heterocyclic compounds |
| HRP20170507T1 (hr) | 2011-06-22 | 2017-06-02 | Purdue Pharma Lp | Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe |
| SMT202100546T1 (it) | 2011-09-19 | 2021-11-12 | Orexo Ab | Compresse per via sublinguale resistenti all'abuso comprendenti buprenorfina e naloxone |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| BR112019001398A2 (pt) | 2016-07-29 | 2019-05-07 | Janssen Pharmaceutica Nv | métodos para tratamento de câncer de próstata |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| US5198459A (en) | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US5232934A (en) | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| US5556837A (en) | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
| US5762925A (en) | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
| AU742391B2 (en) | 1997-08-20 | 2002-01-03 | Regents Of The University Of California, The | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
| EP0943683A1 (en) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Human vanilloid receptor homologue Vanilrep1 |
| TR200101649T2 (tr) * | 1998-12-14 | 2001-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Piperazin türevleri. |
| PT1161424E (pt) * | 1999-03-03 | 2004-08-31 | Wyeth Corp | Novos derivados de diazole como agentes serotonergicos |
| GB9907097D0 (en) | 1999-03-26 | 1999-05-19 | Novartis Ag | Organic compounds |
| US6109269A (en) | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| ATE328868T1 (de) | 2000-08-21 | 2006-06-15 | Pacific Corp | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| AU2001280229B2 (en) | 2000-08-21 | 2006-12-07 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| PE20030417A1 (es) | 2001-09-13 | 2003-08-06 | Smithkline Beecham Plc | Derivados de urea como antagonistas del receptor vainilloide |
| CN1627944A (zh) | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂 |
| ES2316777T3 (es) | 2002-02-15 | 2009-04-16 | Glaxo Group Limited | Moduladores de receptores vainilloides. |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20030158188A1 (en) | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US6974818B2 (en) * | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
-
2003
- 2003-02-27 US US10/374,863 patent/US6974818B2/en not_active Expired - Lifetime
- 2003-02-28 ES ES03743718T patent/ES2295609T3/es not_active Expired - Lifetime
- 2003-02-28 WO PCT/US2003/006107 patent/WO2003074520A1/en not_active Ceased
- 2003-02-28 DK DK03743718T patent/DK1487829T3/da active
- 2003-02-28 JP JP2003572988A patent/JP4663984B2/ja not_active Expired - Fee Related
- 2003-02-28 PT PT03743718T patent/PT1487829E/pt unknown
- 2003-02-28 DE DE60316779T patent/DE60316779T2/de not_active Expired - Lifetime
- 2003-02-28 AT AT03743718T patent/ATE375341T1/de active
- 2003-02-28 AU AU2003225617A patent/AU2003225617A1/en not_active Abandoned
- 2003-02-28 EP EP03743718A patent/EP1487829B1/en not_active Expired - Lifetime
-
2005
- 2005-10-07 US US11/246,498 patent/US7342017B2/en not_active Expired - Lifetime
-
2008
- 2008-01-08 CY CY20081100025T patent/CY1107850T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525365A5 (https=) | ||
| JP2005521679A5 (https=) | ||
| RU2348617C2 (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| JP2013500304A5 (https=) | ||
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| JP2012507567A5 (https=) | ||
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| JP2013505946A5 (https=) | ||
| JP2007518805A5 (https=) | ||
| BR0207872A (pt) | Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração | |
| JP2013512898A5 (https=) | ||
| CN1290504C (zh) | 含有combretastatin和抗癌剂的复合药物 | |
| CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
| JP2008542444A5 (https=) | ||
| CA2604581A1 (en) | Combinations, methods and compositions for treating cancer | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| MX2025005392A (es) | Composicion farmaceutica que comprende un inhibidor de aak1 | |
| RU2009111387A (ru) | Фармацевтические композиции для лечения грибковых инфекций | |
| CA2679047A1 (en) | Methods and compounds for the targeted delivery of agents to bone for interaction therewith | |
| JP2011508779A5 (https=) | ||
| CO5080752A1 (es) | INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB | |
| JP2008534541A5 (https=) | ||
| JP2004533986A5 (https=) |